Introduction
B-cell chronic lymphocytic leukemia (B-CLL), the most common leukemia of adults in Western countries, 1 is a heterogenous disease with prognostic factors like lymphocyte doubling time, serum b 2 -microglobulin, lactate dehydrogenase (LDH), cytogenetics, IgVH mutational status and ZAP-70 expression. [1] [2] [3] [4] [5] The prognostic subgroups might require different therapeutical strategies.
Currently available therapies with the exception of allogeneic stem cell transplantation do not have the potential to cure patients with B-CLL, and are associated with significant toxicities in subgroups of B-CLL patients. [5] [6] [7] Immunotherapy might constitute an advantageous therapeutical option for patients in early stages of the disease, especially with unfavorable prognostic factors. The tumor burden is relatively low and slowly progressing in these patients, thus allowing sufficient time for the generation of an immune response against leukemic cells. One of the mechanisms by which B-CLL cells evade killing by the immune system is the impairment of their function as antigen-presenting cells. [8] [9] [10] The stimulation of T cells by tumor cell lysate-pulsed DCs has been demonstrated in vitro in B-CLL. 10, 11 We therefore wondered if the application of ex vivogenerated dendritic cells (DCs) pulsed with tumor lysates or apoptotic bodies might help to improve the antileukemic immune response in B-CLL patients.
DCs constitute the most potent antigen-presenting cells, with the unique ability to initiate and maintain primary immune responses. They are efficient at antigen capture and antigen presentation to T cells. 12 Different strategies have been applied in clinical trials to deliver antigens to DCs: 12 DCs can be pulsed with synthetic peptides or truncated proteins derived from known tumor-associated antigens (TAAs) 12 or DCs might be transfected with the mRNA of TAAs. The objective of the present study was to investigate the ability of tumor-loaded DCs to stimulate antitumor immunity in patients with B-CLL in early clinical stage.
Materials and methods

Patients characteristics
Nine previously untreated patients with B-CLL in early stages (three female and six male patients) aged 47-78 years (mean 64.2) were included in the present study. The study protocol was approved by the Ethics Committee of the University of Lublin, and all participants gave their written informed consent. Patients were required to have adequate liver and renal function tests (bilirubin, serum creatinine), an ECOG score less than 3 and a life expectancy of at least 6 months. The treatment was carried out at the Department of Hematooncology, University of Lublin Medical School, Lublin, Poland. The clinical characteristics of the patients are summarized in Table 1 .
Healthy donors of peripheral blood for the preparation of DCs DC precursors were obtained from peripheral blood mononuclear cells (PBMCs) taken by leukapheresis from unrelated healthy donors. Patients received DCs from different donors.
Preparation of the lysate/apoptotic bodies
PBMCs from leukapheresis were separated by gradient centrifugation (Gradisol-L, Aqua Medica, Lodz, Poland). A total of 7 Â 10 7 leukemic B cells isolated (CD19 MicroBeads and VarioMACS, Miltenyi-Biotec, Bergisch Gladbach, Germany) from the PB of the respective patient were homogenized by five repeated cycles of freezing to À801C and thawing. Supernatants were passed through a 0.2-mm-pore filter and aliquots stored at À801C until use.
To produce apoptotic bodies, isolated leukemic cells were lethally irradiated with gamma rays (1000 Gy). A suspension of these apoptotic bodies was used for the pulsing of DCs.
Generation of dendritic cells
Isolated PBMCs were used for the generation of monocytederived DCs. Cells were allowed to adhere to plastic dishes for 90 min at 371C. Thereafter, the adherent fraction of PBMCs was cultured in a standard medium containing RPMI-1640 supplemented with 1% human albumin (ZLB Bioplasma AG, Bern, Switzerland), 100 IU/ml penicillin, 50 mg/ml streptomycin and 100 mg/ml neomycin. Then, 1000 IU/ml rhGM-CSF (Leucomax s , Novartis, Basel, Switzerland) and 50 ng/ml rhIL-4 (Strathmann, Hannover, Germany) were added on days 1, 3 and 5 of the culture. On day 6, the lysate of 7 Â 10 7 leukemic B cells or apoptotic bodies was used for the pulsing of the DCs. On day 8, 50 ng/ml rhTNF-a was added to the culture and the cells were stimulated for 2 h. Thereafter, cells were collected, washed twice in 0.9% NaCl and resuspended in 1 ml of 0.9% NaCl. The number of the generated DCs was in the range of 9-87 Â 10 6 (mean 32 Â 10 6 ) with a viability determined by Trypan blue assay of 490%.
Vaccination with dendritic cells
Eligible patients received 4-5 injections with DCs at a 2-3 weeks interval, followed by booster vaccinations administered twice at a 5-6 months interval. Vaccine preparations were administered intradermally in close vicinity to axillar and inguinal lymph nodes.
Immunological evaluation (overview/synopsis)
To evaluate immune responses to DC vaccines in CLL patients, the intracellular concentration of cytokines was measured and changes in the phenotype of PB cells before and after each vaccination were assessed. In all patients, the expression of RHAMM/CD168 as well as of the HLA-A2 antigen was investigated. In HLA-A2-positive patients, specific cytotoxic T lymphocyte (CTL) responses against RHAMM/CD168 were assessed.
Assessment of cytokine concentrations
The serum level of interleukin (IL)-2, IL-4, IL-5, IL-10, TNF-a and INF-g in the PB was measured by the Human Th1/Th2 Cytokine Cytometric Bead Array (Becton Dickinson, Heidelberg, Germany) using a FACSCalibur flow cytometer equipped with CellQuestt software (Becton Dickinson).
Immunophenotyping of the cells
The expression of the following cell surface antigens on the lymphocytes of each patient was determined: CD14/CD45, CD3/CD19/CD69, CD3/CD19/CD25, CD3/CD19/CD95, CD4/ CD8/CD69, CD4/CD8/CD25 and CD4/CD8/CD95 (Becton Dickinson).
Culture of cell lines
T2 cells were obtained from 'Deutsche Sammlung von Zellen und Mikroorganismen' (www.dszm.org, Braunschweig, Germany) and cultured in a standard medium.
mRNA preparation, reverse transcription and reverse transcriptase-polymerase chain reaction
For the isolation of mRNA from PBMCs isolated by Ficoll density gradient centrifugation, the mMACS mRNA Isolation Kit (Miltenyi Biotec, Bergisch Gladbach, Germany) was used according to the manufacturer's instructions. A 50 ng portion of mRNA was reverse transcribed into 20 ml of cDNA using a First Strand cDNA Synthesis Kit for reverse transcriptase-polymerase chain reaction (RT-PCR) (AMV) (Roche Diagnostics, Mannheim, Germany). The expression of RHAMM/CD168 was determined as described earlier. 13 Mixed lymphocyte peptide culture and IFN-g and Granzyme B ELISPOT assay Mixed lymphocyte peptide culture (MLPC) for 2 weeks followed by IFN-g and Granzyme B ELISPOT assays were performed as described earlier. 
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Results
Quality control of the vaccine preparations
All vaccine preparations were highly enriched with mature DCs. More than 90% of the cells were characterized by a large size and dendritic veils as assessed by light microscopy, displaying a DC-like phenotype in flow cytometry 
Clinical responses
Eight of the nine patients completed the treatment with DC vaccinations according to the schedule. In one patient, a disease progression characterized by an increase in WBC occurred 2 months after a course of four DC vaccinations at a 2-3 weeks interval, 5 months after the start of the therapy. This patient was put on a therapy with alemtuzumab (Campatht), but was found to be resistant to this treatment. Further therapies included chlorambucil, then chlorambucil combined with prednisone and cyclophosphamide followed by mantle field irradiation of lymph nodes. Stable disease was achieved until present. A decrease in WBC and PB lymphocytes was observed in most patients in the first days after vaccination with allo-DCs. The median WBC and lymphocyte counts observed during the immunotherapy with DCs are summarized in Figure 1a and b. Immunophenotyping of PB lymphocytes showed a decrease of CD19 þ /CD5 þ leukemic cells in most patients after vaccination with DCs ( Figure 1c) . The changes in the WBC count of patient # 2 are displayed in Figure 2 . In patients # 3, # 4 and # 7, a transient decrease in the WBC count could be noted during the period of immunotherapy (Figure 1a) . In patient # 3, the WBC decreased from 51.9G/l before the start of the therapy to 32.1G/l on the second and fifth day after the second vaccination (Table 2) . A decrease of WBC was observed when DCs were administered every 2-3 weeks. At 23 months after the start of the immunotherapy, the WBC and lymphocyte count remained unchanged in four patients. No significant changes in the size of peripheral lymph nodes, spleen or liver were noted during the treatment period and during the first year after the vaccinations, as assessed by ultrasound examination. There was no difference in terms of clinical response between the patient groups treated with DCs pulsed with tumor cell lysate or apoptotic bodies. The common observation for all patients was the increase of T lymphocytes after the first DC injection; CD8/CD25 double-positive lymphocytes showed a tendency to increase during the time of observation after DC vaccination (data not shown).
Evaluation of Th1/Th2 response
The levels of IL-2, IL-4, IL-5, IL-10, TNF-a and IFN-g were measured by FACS analysis as described in 'Materials and methods'. Vaccination with allo-DCs induced both T helper-1 (Th1) and T helper-2 (Th2) responses with the preponderance of Th1 cytokines (Figure 3 ).
Assessment of RHAMM/CD168 in B-CLL cells by RT-PCR and measurement of RHAMM-specific responses by ELISPOT
RHAMM/CD168 expression was detected in six of the nine CLL patients (Table 2 ). For these HLA-A2-positive patients, MLPC and subsequently ELISPOT assays were performed to assess the frequency of RHAMM/CD168-specific lymphocytes. In one of these patients (patient # 3), enhanced CTL responses against the RHAMM/CD168 peptide R3 were observed (Figures 4 and 5) after four DC vaccinations. In this patient, a decrease of WBC after DC vaccination could be noted. The disease remained stable till present. No specific CTL response against RHAMM/ CD168 could be detected in the HLA-A2-positive patients # 2, # 6 and # 8 ( Table 2) . In patient # 6, neither CTL responses against IMP nor against R3 but unspecific T-cell reactivity elicitable by stimulation with a lectin could be observed. The disease Immunotherapy of B-CLL with pulsed allogeneic DC I Hus et al remained stable till present in patients # 1-5. In patients # 6-9, a progressive increase of the WBC was observed during the immunotherapy with DCs and thereafter.
Toxicity
All vaccinations were well tolerated and no severe side effects were associated with the intradermal injections of pulsed DCs. By the second DC vaccination, all patients developed a mild local reaction (erythema, induration, pruritus) at the vaccination site, which in all cases resolved within 10 days. The clinical follow-up of the patients did not reveal any further toxicity in the first 12 months after the vaccinations. No signs of autoimmunity were detected, as measured by rheumatoid factor, C-reactive protein and anti-nuclear antibodies. The results of in vitro studies on DCs conducted hitherto in CLL are divergent. Vuillier et al 22 and Rezvany et al 23 showed that DCs generated from PBMCs of CLL patients displayed a normal function but an abnormal cytokine pattern with spontaneous high IL-10 secretion. This cytokine production might result in an alteration in the function of the DC pool. 24 Orsini et al 9 demonstrated that DCs in the circulating compartment of patients with CLL are severely impaired and unable to stimulate an effective T-cell response. However, Goddard et al have shown that with the appropriate culture conditions, including additional cytokines, morphologically and functionally normal DCs can be generated from patients with B-CLL. 10, 11 CLL-DCs were morphologically and phenotypically immature, lacking the maturation antigen CD83 and the costimulatory molecule CD80 and therefore being unable to induce a significant response in an allogeneic mixed lymphocyte reaction (MLR) with a reduced ability to release IL-12 and driven to a Th2 response. Only weak T-cell responses against unstimulated CLL cells have been observed in autologous MLRs. 25 Taking into account the above limitations concerning DC function and the low monocyte count in CLL patients, in our study we used DCs generated from PB monocytes of healthy donors.
We used allogeneic DCs in order to recruit helper T cells, thereby avoiding the need for additional HLA class II-restricted Figure 2 WBC count trend curves of patient # 2 from the time of initial diagnosis of B-CLL to 12 months after the end of DC immunotherapy. The time course of the patient's visits to hospital is indicated. Blood was drawn on each visit. DC vaccines were administered at the time points indicated by the black vertical arrows. The initial WBC count was set as 100%, bringing the logarithmic values to 2. Based on the distribution analysis, one can assume that each deviation 715% is statistically significant. To compare the WBC count values from the start and the end of the follow-up period, in four patients the Wilcoxon test was used.
Immunotherapy of B-CLL with pulsed allogeneic DC I Hus et al tumor antigens. Different HLA-mismatched donors were recruited for each immunization to enable cognate TAA recognition by avoiding dominant allospecific responses. In the present study, for the first time DC vaccines were administered to CLL patients. In most patients, a decrease of WBC count, lymphocytes and CD19 þ /CD5 þ cells was observed in the first days after DC vaccinations. In four patients, a decrease in WBC during the immunotherapy was detected and the disease remained stable over 23 months after the start of DC vaccination. In our study, the effect of vaccination was only seen when subsequent injections were given every 2-3 weeks. A longer effect might be achieved with an increased number of vaccines. Moreover, the variation of lymphocyte counts following vaccination might also be related to a recirculation effect.
As for T-cell responses to leukemic cells in CLL patients, B lymphocytes in CLL characteristically express low amounts of surface immunoglobulin, and T cells from these patients have been reported to display an impaired functional activity. 8 Scrivener et al 26 suggest that the profound T-cell dysfunction in B-CLL characterized by the aberrant expression of several surface molecules on T lymphocytes is due to the interaction with malignant B cells. Gitelson et al 27 demonstrated that tumor-reactive T cells exist in some CLL patients mainly during early stages of the disease and that these T cells might potentially mediate therapeutic responses. 28 HLA class IIrestricted proliferative and cytotoxic T-cell responses to B-CLL could be generated using autologous DCs pulsed with tumor cell lysates. 10 Mü ller et al 29 demonstrated effective T-cell responses induced in vitro by RNA-transfected DCs in CLL patients. As confirmed by cytokine measurement before and after vaccination with allo-DC, our immunotherapy induced both Th1 and Th2 responses, with emphasis on the Th1 response, suggesting an active antitumor response. Induction of a Th1-dominant immune response by DC vaccines was described in solid tumors, metastatic renal cell carcinoma 30 and melanoma. 31, 32 Rieser et al 33 observed clinical responses to DC immunotherapy only in patients where a Th1 dominant response was observed, suggesting that this type of response is required for the induction of tumor regression.
Using the SEREX technique, we recently identified the receptor for hyaluronic acid-mediated motility (RHAMM/ CD168) as a TAA eliciting both tumor-specific humoral and T cellular immune responses in RHAMM/CD168-expressing AML and CML patients. 34, 35 Expression of RHAMM/CD168 was found also in CLL cells, and specific CTL responses against the RHAMM/CD168-derived peptide R3 could be generated in vitro in CLL patients (Giannopoulos et al. Haematologica 2005; 90: 228; abstract). Immunotherapy of B-CLL with pulsed allogeneic DC I Hus et al Specific CTLs against RHAMM/CD168 were detected in one of the four RHAMM/HLA-A2 double-positive patients of the present study. In this particular patient, the decrease of WBC after DC vaccination was the most profound. RHAMM/CD168 might be one of the antigens responsible for the induction of CTLs specific for CLL cells, and therefore requires further evaluation.
Immunotherapy with allogeneic DCs stimulated with tumor cell lysates or apoptotic bodies in this study was demonstrated to be feasible, safe and well tolerated. To improve the clinical response, one may consider the use of autologous DCs instead of allogeneic DCs to work in an HLA-identical setting, other methods of DC generation and stimulation, an increase in the number of vaccines or the addition of adjuvants like GM-CSF, CpG-rich oligonucleotides or keyhole limpet hemocyanin. The lack of adverse events in concert with some positive immunophenotype changes justifies further investigation on this novel therapeutic approach. Enhancement of specific CTL responses against RHAMM/ CD168-derived T-cell epitope peptide R3 after allo-DC lysate vaccination in patient # 3 of Table 2 . ELISPOT assays were performed to evaluate the release of IFN-g and Granzyme B by CD8 þ T lymphocytes prepared from the PB of patient # 3 of Table 2 . The CD8 þ cells were presensitized with the R3 peptide as described in Materials and methods for 1 week. On day 8, the reactivity of the primed CD8 þ T cells was assessed with R3-pulsed T2 cells. T2 cells without peptide served as a negative control, and T2 cells pulsed with the influenza matrix protein peptide (IMP) as a positive control.
